Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608558 | 0.86 | TSHR (0.76) | CYP19A1ALDH1A1POLBNAMPTTSHR | |
| SCHEMBL4662858 | 0.86 | CYP19A1 (0.74) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL20946439 | 0.85 | CYP19A1 (0.72) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL10047336 | 0.83 | CYP19A1 (0.76) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL5444153 | 0.83 | CYP19A1 (0.66) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL26229835 | 0.82 | CYP19A1 (0.69) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL30504862 | 0.82 | CYP19A1 (0.72) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL5444156 | 0.82 | CYP19A1 (0.72) | CYP19A1ALDH1A1POLBMEN1GAA | |
| SCHEMBL5458763 | 0.81 | ALDH1A1 (0.64) | CYP19A1ALDH1A1NAMPTL3MBTL1TSHR | |
| SCHEMBL5458079 | 0.81 | KEAP1 (0.69) | ALDH1A1POLBL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | CYP19A1 235/4885ALDH1A1 816/4885POLB 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.